2638 Effectiveness of 2nd-line and subsequent therapies after pazopanib (Paz) in patients (pt) with metastatic renal cell carcinoma (mRCC): Final results of the SPAZO study (SOGUG)
Arija, J.A. Arranz, Pérez-Valderrama, B., González-Larriba, J.L., Rodríguez Sánchez, A., Chirivella, I., Pinto, A., Marrero, R.D. García, Rubio, G., García, J.M. Jurado, Borrega, P., Quintela, M. LázaVolume:
51
Language:
english
Journal:
European Journal of Cancer
DOI:
10.1016/s0959-8049(16)31455-1
Date:
September, 2015
File:
PDF, 63 KB
english, 2015